New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma
- PMID: 23382112
- DOI: 10.1158/1078-0432.CCR-12-3796
New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma
Abstract
The modified Response Evaluation Criteria in Solid Tumors (mRECIST) guideline has introduced specific amendments to standard RECIST to address the unique complexities involved in the evaluation of tumor response in hepatocellular carcinoma. A growing amount of data suggests that mRECIST, designed for response assessment in clinical trials, may translate into a tool for clinical practice.
Comment on
-
Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization.Clin Cancer Res. 2013 Mar 15;19(6):1503-11. doi: 10.1158/1078-0432.CCR-12-2721. Epub 2012 Dec 7. Clin Cancer Res. 2013. PMID: 23225115
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
